Technical.ly22h
This pharma startup backed by Y Combinator aims to treat multiple diseases, for good
Montgomery County’s SFA Therapeutics — led by the scientist behind Effexor and Rapamune — is in it for the long haul, with promising results.
Head-to-Head Preclinical Studies of SFA-002 as a Novel Psoriasis Treatment Presented at the 2025 American Academy of Dermatology Annual Meeting
SFA Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oral small-molecule biosynthetic ...
MyChesCo on MSN5d
SFA Therapeutics Reports Promising Phase 1b Results for Oral Psoriasis Treatment
SFA Therapeutics, Inc. has announced encouraging results from its Phase 1b clinical trial of SFA-002, an oral drug candidate ...
Yahoo Finance7d
SFA Therapeutics Announces Positive Phase 1b Data of SFA-002 in Mild-to-Moderate Psoriasis
SFA Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing oral small-molecule biosynthetic compounds for the treatment of inflammatory and autoimmune diseases. Based on ...
MyChesCo on MSN4mon
SFA Therapeutics Strengthens Patent Portfolio for Key Drug Candidates
JENKINTOWN, PA — SFA Therapeutics, Inc., a biotech firm specializing in autoimmune diseases and hepatocellular carcinoma, ...
Morningstar6d
Head-to-Head Preclinical Studies of SFA-002 as a Novel Psoriasis Treatment Presented at the 2025 American Academy of Dermatology Annual Meeting
Mice dosed with SFA-002 displayed reduction in psoriasis disease severity and greater reduction in skin thickening compared to etanercept and apremilast in the in vivo model SFA-002 reduced key ...
Yahoo Finance6d
SFA Therapeutics Announces Positive Phase 1b Data of SFA-002 in Mild-to-Moderate Psoriasis
JENKINTOWN, Pa., March 7, 2025 /PRNewswire/ -- SFA Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oral small-molecule biosynthetic compounds for the treatment of ...